IL6R and rheumatoid arthritis: Trials comparing bDMARDs specifically inhibiting IL-6 receptor or ligand to placebo in patients with established RA with inadequate response (IR) to methotrexate (MTX) or conventional synthetic disease-modifying drugs (csDMARDs) showed effective reduction of signs and symptoms for several anti-IL-6R agents, including TCZ (Korean patients),13 SAR12 27 28 and BCD-089 (levilimab).29 Baseline characteristics and detailed efficacy outcomes are shown in online supplemental tables S2.3.1.1 and S2.4.1.1.